A Randomized Phase Ii Trial Of Fulvestrant With Or Without Ribociclib After Progression On Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/ 6 Inhibition In Patients With Unresectable Or Metastatic Hormone Receptor Positive, Her2 Negative Breast Cancer (Maintain Trial)
CANCER RESEARCH（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要